Hematology/oncology and stem cell therapy最新文献

{"title":"Post hematopoietic stem cell transplant (HSCT) outcomes in pediatric intensive care unit, experience from a referral center for cellular therapy and hematopoietic stem cell transplantation.","authors":"Hussain AlAbdullah, Fawaz Alanzi, Raghad Alhuthil, Tahani Alshaibani, Nourah AlBeeshi, Ali Alqahtani, Moath Alabdulsalam, Tareq Alayed, Abdullah Alturki, Tariq Alofisan, Fahad Aljofan","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00022","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00022","url":null,"abstract":"<p><strong>Background: </strong>Patients who underwent hematopoietic stem cell transplantation (HSCT) are considered at high risk for pediatric intensive care unit (PICU) admission. Therefore, this study aimed to assess outcomes and mortality-related risk factors among pediatric HSCT recipients admitted to the PICU.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted at a Saudi Arabian tertiary care center and involved pediatric patients (aged 4 weeks to 14 years) who underwent HSCTs between January 2015 and December 2019 and were admitted to the PICU.</p><p><strong>Results: </strong>Of the 173 pediatric HSCT recipients admitted to the PICU, 65.3% were admitted for respiratory failure. Graft-versus-host disease and chronic infections affected 48.6% and 71.7% of the cases, respectively. Pulmonary hemorrhage and veno-occlusive disease occurred in 15.0% and 32.4% of the patients, respectively. Ventilation and inotropic support were administered to 79.8% and 41.0%, respectively. Acute kidney injury (AKI) occurred in 47.4% of the patients, of which 23.2% required continuous renal replacement therapy/hemodialysis. The PICU survival rate was 59.0% (102/173), and the mortality rate was 41.0% (71/173). In the univariate analysis, chronic infection, pulmonary hemorrhage, ventilation, inotropic support, AKI, higher PRISM III score, and prolonged PICU stay were associated with mortality (P < 0.05). In the multivariable analysis, only prolonged PICU stay (P = 0.016), AKI (P = 0.040), inotropic support (P < 0.001), and ventilation (P = 0.017) showed potential association with mortality.</p><p><strong>Conclusion: </strong>Early recognition and targeted interventions for these complications are crucial for improving outcomes in this vulnerable population. More research is needed to validate these findings and optimize care practices for HSCT recipients in the PICU setting.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"227-232"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of plerixafor on the hemostatic system in patients undergoing stem cell mobilization.","authors":"Özge Koç, Özlem Doğan, Uğur Şahin, Ekin Kircali, Derya Koyun, Mutlu Arat, Muhit Özcan","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00006","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00006","url":null,"abstract":"<p><p>Despite numerous reports on the procoagulant activities of G-CSF, the effect of plerixafor on the hemostatic system is not clearly understood. This study aims to evaluate the effects of plerixafor on the hemostatic system when used for autologous stem cell mobilization (ASCM) for poor mobilizers (PM) with lymphoma and multiple myeloma. Patients who were performed ASCM with plerixafor in combination with GCSF were prospectively enrolled. Cohort A included patients mobilized with G-CSF whereas Cohort B included patients mobilized with G-CSF + plerixafor. Blood samples were obtained before the mobilization regimen and just before apheresis. CBC, coagulation tests, CRP, protein C and S, vWF antigen, and factors VIII and XII were studied. Cohort A (n= 30) of which 9 received chemotherapy + G-CSF. Factor VIII, INR, vWF antigen, and CRP significantly increased after G-CSF compared to baseline. Decreases in protein C and S were significant (p<0.001; p=0.005). In cohort B (n=15) no significant changes were observed in coagulation parameters Factor levels, protein C and S before and after the plerixafor. Fibrinogen decreased slightly after plerixafor administration (4.2773±2.2125 vs. 3.6987±1.5062; p=0.02). remained unchanged. In conclusion the addition of plerixafor to G-CSF did not exert further significant procoagulant effects.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"211-218"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, distribution, and patient characteristics of childhood cancer in Jordan: an updated population-based study.","authors":"Ranya Baddourah, Dana Baddourah, Dalia Alsweedan, Mahmoud Al Sheyyab, Omar F Nimri, Suleiman Alsweedan","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00025","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00025","url":null,"abstract":"<p><strong>Background and objectives: </strong>The most recent study on pediatric cancer epidemiology in Jordan was published in 2003. This study aims to provide updated epidemiological data for local clinicians, policymakers, and international physicians interested in Middle Eastern patient populations.</p><p><strong>Materials and methods: </strong>We analyzed data from the Jordanian National Cancer Registry for pediatric patients (ages 0-18) diagnosed between 2000 and 2017, classified according to the International Classification of Childhood Cancer, third edition.</p><p><strong>Results: </strong>Our cohort comprised 7639 patients. The mean age at diagnosis was 8.68 years, with a male-to-female ratio of 1.4 and an annual incidence rate of 191 per million population. We identified significant differences in cancer distribution between Jordan and neighboring Middle Eastern countries, as well as regional discrepancies in the number of diagnosed childhood cancer cases. A comparison of cancer incidence between 1996-1998 and 2000-2017 in Jordan was conducted. Our findings align with established trends, such as the correlation between the male-to-female cancer incidence ratio and GDP per capita.</p><p><strong>Conclusion: </strong>This study provides the latest organized and accessible data on childhood malignancies in Jordan.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"233-238"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired factor XIII deficiency in myeloid neoplasms: case series and review of literature.","authors":"Alfadil Haroon, Mostafa F Mohammed Saleh, Ali Alahmari, Syed Osman, Ahmed Alotaibi, Hazzaa Alzahrani, Mahmoud Aljurf","doi":"10.4103/hemoncstem.hemoncstem-D-24-00034","DOIUrl":"10.4103/hemoncstem.hemoncstem-D-24-00034","url":null,"abstract":"<p><p>Acquired factor XIII (FXIII) deficiency is a rare disorder that could be associated with autoimmune and malignant disorders with a high risk of bleeding. In acute leukemias, acquired FXIII deficiency has been reported and replacement of FXIII helped to control significant bleeding. Here, we report four cases of myeloid neoplasms to have acquired FXIII deficiency with interesting concomitant RUNX1 mutation in the molecular background of two patients. Correction of bleeding complications was successful in all patients with FXIII substitution by FXIII concentrate in three patients and cryoprecipitate in one patient. Studying the association of FXIII deficiency with molecular abnormalities in such neoplasms is needed for better understanding and detection of common pathophysiologic pathways. This could help to avoid severe bleeding during diagnostic or therapeutic interventions in patients at risk.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"245-247"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of immature platelet fraction measurement in predicting hematologic recovery in patients with acute leukemias undergoing high-intensity chemotherapy and stem cell transplantation.","authors":"Ana Beatriz Sánchez López, Rolando Humberto Martínez Cordero, Gloria Patricia Duarte Luque, Rose Mary Jaramillo Calle, Melody Mary Lever Hawkins, Lina María Sopó Martínez, Alexandra Porras Ramírez, Alejandro Rico Mendoza","doi":"10.4103/hemoncstem.hemoncstem-D-24-00005","DOIUrl":"10.4103/hemoncstem.hemoncstem-D-24-00005","url":null,"abstract":"<p><strong>Background and objectives: </strong>The immature platelet fraction (IPF) count is a parameter that quantifies young and reticulated platelets in peripheral blood, which reflects platelet production in the bone marrow. It has been used as a predictive model for bone marrow recovery in patients with acute leukemia after high-intensity chemotherapy and/or stem cell transplantation. This study aimed to evaluate IPF as a predictor of hematologic recovery in these patients.</p><p><strong>Materials and methods: </strong>A retrospective analysis of patients with acute leukemias after high-intensity chemotherapy or undergoing stem cell transplantation, treated at the Instituto Nacional de Cancerología (INC) (Bogotá, Colombia) between October 2020 and March 2021.The variables studied included age, sex, type of leukemia, type of treatment, type of chemotherapy, treatment duration, peripheral blood platelet count, percentage of IPF (IPF%), and peripheral blood neutrophil count. Univariate and multivariate analyses were carried out to evaluate the relationship between the IPF behavior and hematologic recovery. Statistical analysis was performed using the R package version 4.2.0® (free license).</p><p><strong>Results: </strong>Between October 2020 and March 2021, 32 patients were analyzed, with a median age of 26 years; the male population was 59.4%. Acute lymphoid leukemia was the most frequent type in 62.5%; 43.7% of patients received chemotherapy, while the others underwent allogeneic stem cell transplantation. Hematologic recovery occurred between days 15 and 30. Spearman's correlation was 0.27 with a p=0.13 for recovery day and IPF% (weak correlation).</p><p><strong>Conclusion: </strong>There is limited information regarding the usefulness of IPF% in hematology. The IPF% was not found to be a predictor of hematologic recovery in patients with acute leukemia after chemotherapy and/or allogeneic stem cell transplantation. The lack of correlation does not allow for assuming a reliable cut-off point. Further studies with a larger sample size are needed.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"239-244"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low incidence of primary graft failure with bendamustine, fludarabine, and busulfan conditioning prior to haploidentical allogeneic hematopoietic cell transplantation.","authors":"Ivan Sergeevich Moiseev, Alexandra Nikolaevna Cherkashina, Tatiana Aleksandrovna Rudakova, Nikita Pavlovich Volkov, Dmitrii Konstantinovich Zhogolev, Svetlana Evgenievna Durova, Yulia Yurievna Vlasova, Elena Vladislavovna Morozova, Sergey Nikolaevich Bondarenko, Alexander Dmitrievich Kulagin","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00026","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00026","url":null,"abstract":"<p><p>The outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) have improved with the implication of new in vivo and ex vivo graft-versus-host disease (GVHD) prophylaxis regimens. However, primary graft failure is still reported more frequently in haplo-HCT compared to a matched donor HCT. We conducted a pilot study (NCT04942730) to evaluate the impact of adding bendamustine to fludarabine and busulfan conditioning on engraftment after haplo-HCT. Bendamustine was administered on days -7 and -6 in the 130 mg/m2 dose. Fifty patients with malignant disorders in complete hematologic response were enrolled. The cumulative incidence of engraftment was 98% (95% confidence interval [CI] 77%-99%) with a median of 20 days. One-year overall survival was 67.9% (95% CI 53.2%-86.7%), event-free survival was 68.1% (95% CI 53.4%-86.8%), the cumulative incidence of relapse was 4.9% (95% CI 0.82%-15%), and nonrelapse mortality was 27% (95% CI 13%-44%). Relatively high incidence of viral reactivations (68%, 95% CI: 52%-79%) and invasive fungal infections (19%, 95% CI: 9.3%-32%) were observed. The study justifies further investigation of fludarabine, busulfan, and bendamustine conditioning in haplo-HCT.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"219-226"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion-associated graft-versus-host disease (TA-GVHD) and graft-versus-host disease (GVHD): Pathophysiology and management (contrasted and compared).","authors":"Serena Valsami, Georgios Dryllis, Kassiani Papanastasi, Styliani Kokoris, Anastasios Kriebardis, Konstantinos Nikitiadis, Konstantinos Konstantopoulos, Marianna Politou","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00043","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00043","url":null,"abstract":"<p><p>Transfusion of blood products is a common lifesaving medical procedure in clinical practice. However, it poses the risk of potential adverse reactions for the recipient. Transfusion-associated graft-versus-host-disease (TA-GVHD) is a rare adverse event, fatal in >90% of cases. TA-GVHD pathophysiology is not completely understood involving two factors: (i) underlying immunosuppression and (ii) human leukocyte antigen compatibility between blood donor and recipient. Clinical presentation is not specific, and the difficulty in correlating the clinical syndrome to the transfusion renders diagnosis challenging. As no effective treatment exists to date, irradiation of blood products remains the cornerstone of TA-GVHD prevention. Distinct differences emerge in comparing TA-GVHD to GVHD, a common event of the bone marrow graft to the recipient after allogeneic hematopoietic stem cell transplantation; thus, GVHD may be a helpful disease model used to better understand TA-GVHD. This is a review of TA-GVHD in comparison with GVHD.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"203-210"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"H syndrome: A histiocytosis-lymphadenopathy plus syndrome. A comprehensive review of the literature.","authors":"Alaa Hamad, Hadeel Elwaheidi, Farah Salameh, Mossaed Alyahya, Riad El Fakih, Mahmoud Aljurf","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00004","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00004","url":null,"abstract":"<p><p>H syndrome is a rare autosomal recessive genodermatosis that falls under the histiocytosis-lymphadenopathy plus syndrome. The term \"H syndrome\" includes manifestations such as hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, low height, and occasionally hyperglycemia. The syndrome is associated with mutations in the SLC29A3 gene, which encodes the human equilibrative transporter 3 present in endosomes, lysosomes, and mitochondria. The generalized and ubiquitous presence of affected lysosomes and mitochondria contributes to the systemic and phenotypically heterogeneous manifestations of the syndrome. H syndrome manifestations are cutaneous, systemic, and organ-specific. The pathognomonic signs are hypertrichosis and hyperpigmentation in the inner thighs and shins. However, not all patients present with these symptoms. H syndrome management involves a multidisciplinary approach to address specific symptoms and complications. The prognosis of H syndrome depends on several factors, including the extent and severity of clinical manifestations, the presence of complications, and timely diagnosis and management. Further studies are needed to explore the association between prognosis and the different mutations encountered in H syndrome.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"159-167"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and outcomes of CAR-T cell therapy recipients with septic shock in the United States.","authors":"Aditya Sharma, Aditi Sharma, Ayman O Soubani","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00031","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00031","url":null,"abstract":"","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"200-202"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rehabilitation practices during hematopoietic stem cell transplantation: An international survey.","authors":"Victor F Leite, Sonal Oza, Sara C Parke, Toure Barksdale, Aliea Herbert, Vishal Bansal, Jae Yong Jeon, Orla McCourt, Shinichiro Morishita, Mahmoud D Aljurf, Jack B Fu, An Ngo-Huang","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00007","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00007","url":null,"abstract":"<p><strong>Background and objective: </strong>Rehabilitation therapy plays an important role in treating physical and functional impairments observed in individuals undergoing hematopoietic stem cell transplants (HSCT). This study assessed the rehabilitation practices implemented in the HSCT population internationally.</p><p><strong>Materials and methods: </strong>A 48-question online survey comprising questions soliciting information regarding patient characteristics, therapy details (timing, indication, and administering providers), outcome measures, and precautions were developed by an international group of cancer rehabilitation physicians. As reported by European registries, surveys were administered to personnel providing care to patients receiving HSCT at cancer centers, which comprised the top 10% of HSCT volume. In addition, emails were sent to National Medical Societies and registries in the Latin America, Asia, and Pacific regions.</p><p><strong>Results: </strong>Forty-three institutions from 18 countries responded to the survey. Half of the centers provided referrals for rehabilitation therapy at the time of admission. Referrals were provided for functional decline (84.5%), risk of falls (53.3%), and discharge planning (42.2%). Rehabilitation therapies were administered by physical therapists (93.0%), occupational therapists (34.9%), therapy aides (14.0%), and speech-language pathologists (11.6%). Approximately 95% of the surveyed centers used objective functional measures such as sit-to-stand (46.5%), grip strength (46.5%), and 6-min walk/gait speed (both 34.9%). The blood counts were monitored to determine the appropriateness of the therapy modalities.</p><p><strong>Conclusion: </strong>Rehabilitation practices varied internationally; however, most centers provided skilled therapy during hospitalization for HSCT, utilized objective and patient-reported outcomes, and monitored blood counts to determine the safety of administering therapy.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"176-183"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}